Skip to main content
    N

    Nexalin Technology Inc. (NXL)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $2.45
    -0.06 (-2.39%)

    Market Cap: $2.63M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    25%(2/8)
    Avg Surprise
    -29.97%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-2.91
    Range$-2.91 - $-2.91
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-2.70-7.8%
    60d ago$-2.70-7.8%
    30d ago$-2.70-7.8%
    7d ago$-2.70-7.8%
    Current$-2.91
    Revenue Consensus
    $75000
    Range$75000 - $75000
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-8.31
    Range$-8.31 - $-8.31
    1 analysts
    Revenue Consensus
    $12000
    Range$12000 - $12000
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-8.31---
    Sep 26EST
    		-$-2.91---
    Jun 26
    Reported Aug 12
    		$-0.11$-0.10-10.00%Miss-10.0%
    Mar 26
    Reported May 8
    		$-0.11$-0.12+8.33%Beat+26.7%
    Dec 25
    Reported Mar 25
    		$-0.13$-0.12-8.33%Miss+48.0%
    Sep 25
    Reported Nov 14
    		$-0.13$-0.12-8.33%Miss+43.5%
    Jun 25
    Reported Aug 6
    		$-0.10$-0.14+28.57%Beat+41.6%
    Mar 25
    Reported May 13
    		$-0.15$-0.10-50.00%Miss+96.4%
    Dec 24
    Reported Mar 14
    		$-0.25$-0.12-108.33%Miss+92.1%
    Sep 24
    Reported Nov 8
    		$-0.23$-0.12-91.67%Miss+97.5%
    Jun 24
    Reported Aug 8
    		$-0.17N/AN/ABeat+94.9%
    Mar 24
    Reported May 10
    		$-4.20N/AN/ABeat-4100.2%
    Dec 23
    Reported Mar 27
    		$-3.15N/AN/ABeat-3049.3%
    Sep 23
    Reported Nov 13
    		$-9.29N/AN/ABeat-30878.7%
    Jun 23
    Reported Aug 10
    		$-3.39N/AN/ABeat-5543.5%
    Mar 23
    Reported May 10
    		$-0.10N/AN/ABeat-25.0%
    Dec 22
    Reported Mar 2
    		$-0.10N/AN/ABeat-66.7%
    Sep 22
    Reported Nov 10
    		$-0.03$0.00N/AMiss-
    Jun 22
    Reported Sep 19
    		$-0.06$0.00N/AMiss-
    Mar 22
    Reported Jun 29
    		$-0.08$0.00N/AMiss-
    Dec 21
    Reported Mar 30
    		$-0.06$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.17EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-18480.00%
    ROE-240.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage3484.64x
    Current Ratio1.25xQuick Ratio1.10x
    Trading Statistics
    Beta4.11Avg Volume2.91M
    52-Week High$50.7052-Week Low$2.38

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.87
    SMA 20$4.32
    SMA 50$6.46
    SMA 200$11.90
    EMA 10$3.54
    EMA 20$4.27
    EMA 50$6.20
    EMA 200$13.41

    MACD

    Line: -0.97Signal: -0.84Hist: -0.12

    ADX

    ADX: 32.3+DI: 19.6-DI: 16.8

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down100.0
    PSAR$8.79

    Bollinger Bands

    Upper Band$6.64
    Lower Band$2.01
    %B Position10697%(Upper)
    Band Width0.09

    RSI (14-Day)

    Neutral
    31.1

    Momentum Oscillators

    Stoch %K2.3
    Stoch %D1.5
    Williams %R-96.1
    ROC (10d)-67.5%
    Momentum-5.10
    CCI (20d)-172.1
    MFI (14d)97.8

    Volatility Measures

    ATR (14d)$1.68(68.7%)
    StdDev (20d)1.16
    Hist Vol320.4%(High)

    Volume Flow

    VWAP$2.38
    OBV293.6M
    AD Line102.2B
    CMF (20d)-0.615

    Volume Metrics

    Avg Vol (20d)3.2M
    Vol Ratio0.0x(Low)
    VWMA (20d)$7.44

    Pivot Points

    R3$3.02
    R2$2.86
    R1$2.69
    Pivot Point$2.53
    S1$2.36
    S2$2.20
    S3$2.03

    Advanced Oscillators

    TSI-28.14
    Ultimate Osc29.3
    KST-335.54

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$12,161$14,950$171,895$18,149$70,588$41,015$27,179$36,031$26,840$78,671$20,535$24,113
    Cost of Revenue$3,264$1,817$21,029$3,948$22,838$13,558$7,496$12,694$7,247$9,156$5,231$3,973
    Gross Profit$8,897$13,133$150,866$14,201$47,750$27,457$19,683$23,337$19,593$69,515$15,304$20,140
    Operating Expenses$2.26M$2.13M$2.56M$2.36M$1.67M$2.04M$2.90M$2.53M$1.32M$1.14M$1.64M$2.44M
    R&D$564,480$346,382$224,940$226,520$225,774$406,288$737,241$178,565$169,410$105,668$0$0
    SG&A$1.69M$1.79M$2.34M$2.13M$1.44M$1.63M$2.16M$2.35M$1.15M$1.04M$-282,034$2.44M
    Operating Income$-2,247,315$-2,119,902$-2,413,167$-2,345,631$-1,620,858$-2,011,225$-2,875,396$-2,508,517$-1,297,021$-1,073,712$-1,624,473$-2,415,537
    Interest Income$8,016$21,025$27,609$46,774$32,438$20,119$37,195$56,250$11,719$24,946$51,287$82,943
    Interest Expense$-129$-34$-159$-2,288$-4,690$-1,103$-1,823$-1,000$-66$-304$-595,850$5,330
    Income Before Tax$-2,239,170$-2,096,837$-2,376,546$-2,276,311$-1,580,987$-1,987,289$-2,833,475$-2,448,416$-1,283,202$-1,046,940$-780,669$-2,297,189
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,239,170$-2,096,837$-2,376,546$-2,276,311$-1,580,987$-1,988,337$-2,833,275$-2,448,257$-1,284,493$-1,041,157$-780,669$-2,297,189
    EBITDA$-2,224,253$-2,107,053$-2,398,162$-2,319,900$-1,612,989$-2,003,725$-2,868,052$-2,501,454$-1,291,195$-1,069,528$-1,426,059$-2,373,915
    EBIT$-2,247,315$-2,117,896$-2,404,314$-2,325,373$-1,618,115$-2,008,511$-2,872,493$-2,505,666$-1,294,987$-1,072,190$-1,427,806$-2,374,802
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NXL

    News

    Nexalin Technology, Inc. SEC Filing (Oct 16, 2026)

    This article reports on an SEC filing by Nexalin Technology, Inc. (NXL) regarding the effectiveness of its S-1 registration statement, with an effectiveness date of October 15...

    Stock Titan•10/16/26•Neutral

    Nexalin Technology regains compliance with Nasdaq MBPR

    Nexalin Technology announced it has regained compliance with Nasdaq's minimum bid price requirement after its common stock traded above $1.00 for 21 consecutive days following a reverse stock split. The company must...

    Medical Buyer•10/9/26•Bullish

    Form S-1/A Nexalin Technology Inc For: 9 October By Investing.com

    This article announces that Nexalin Technology Inc. filed a Form S-1/A on October 9. The filing indicates a significant corporate action or update for the company. The brief mention suggests readers should refer...

    Investing.com India•10/9/26•Neutral

    Form S-1/A Nexalin Technology Inc For: 9 October By Investing.com

    This article reports on the filing of Form S-1/A by Nexalin Technology Inc. for October 9th. It includes various financial market data such as indices, commodities, and bond prices...

    Investing.com Nigeria•10/9/26•Neutral

    Form S-1/A Nexalin Technology Inc For: 9 October By Investing.com

    The article announces the filing of Form S-1/A by Nexalin Technology Inc. on October 9. This regulatory filing is a public document that companies submit to the SEC...

    Investing.com Canada•10/9/26•Neutral

    NXL Valuation and Fair Value

    P/E
    -0.2x
    P/B
    1.1x
    See GNG's fair value

    NXL Profitability: Margins, ROIC and FCF

    Gross margin
    86.2%
    Operating margin
    -18480.0%
    Net margin
    0.0%
    ROE
    -240.2%
    FCF margin
    -2860.5%

    NXL Competitors

    CompanyTicker
    VivoSim Labs, Inc.VIVS
    iSpecimen IncISPC
    INVO Fertility, Inc.IVF
    Biomotion Sciences Ordinary SharesSLXN
    HCW Biologics IncHCWB
    Kairos Pharma, Ltd.KAPA
    Painreform LtdPRFX
    Matinas BioPharma Holdings IncMTNB

    Sector: Healthcare

    NXL Bull Case vs Bear Case

    Bear case

    • NXL beat EPS estimates in 25.0% of its last 8 reported quarters.
    • NXL's quarterly revenue changed -82.8% year over year.

    NXL Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -30.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-2.91
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About NXL

    Does NXL pay dividends?

    Nexalin Technology Inc. (NXL) does not currently pay a regular dividend.

    What is NXL's market cap?

    Nexalin Technology Inc. (NXL) has a market capitalization of $2.63M with a current stock price of $2.45.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In